- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- IgAN
- Events
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefR
- Radiology Toolkit
- On Demand Webinars
- Infographics
- Podcasts
- Videos
- Request a Presentation
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Major Depressive Disorder In Chronic Kidney Disease
A joint virtual live event for NephU & PsychU members.
In this virtual live event, Alf Carroll, MS, PA-C, and Alyssa Peckham, PharmD, BCPP discuss the high prevalence of major depressive disorder (MDD) among patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).
Major depressive disorder affects more than 260 million people worldwide.1 The reported prevalence of depression in patients with chronic kidney disease ranges from 20-65%.2 This webinar provides an overview of both MDD and CKD and discusses their overlap of symptomology.
1World Health Organization. Fact Sheet on Depression. (2012) https://www.who.int/health-topics/depression#tab=tab_1
2Teles F et al. Clinics (Sao Paulo). 2014 ;69(3):198-202.Alf Carroll and Dr Alyssa Peckham are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).
Featured Speakers
Alf Carroll, MS, PA-C
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Alf Carroll, MS, PA-C is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. He earned his Bachelor of Science in Biology and Master of Science in Physician Assistant Studies from Northeastern University in Boston, Massachusetts. He worked clinically as a Physician Assistant in the Emergency Department at Massachusetts General Hospital and South Shore Hospital in the Boston area. Prior to joining Otsuka, Alf held a position at AstraZeneca Pharmaceuticals on their Market Access team focusing on large health systems in New England, covering the cardiovascular, renal, endocrine, and respiratory therapeutic areas.
Alyssa Peckham, PharmD, BCPP
Medical Science Liaison, Neuroscience-
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Areas of Expertise:
- Addiction Medicine
- Mood Disorders
- Anxiety
- Schizophrenia
- Psychopharmacology
- Public Health
Location
Online
Join Today for Instant Access to all NephU Offerings.
Membership is free!
Join NephU today at no cost to register for this event and access to other premium content.
- The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
- Quickly learn more about the topics that interest you.
- Access our library of on-demand kidney health resources
- Gain key insights from industry experts & though leaders.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.